(FXL) |
| 0 (0%) 10-10 16:16 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 173.67 |
| Resistance 1: | 169.81 |
| Pivot price: | 169.73 |
| Support 1: | 163.58 |
| Support 2: | 136.10 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Fri, 10 Oct 2025
Is Fuyo General Lease Co. Ltd. (FXL) stock a fit for income portfolios - Weekly Market Outlook & Daily Profit Focused Screening - newser.com
Fri, 10 Oct 2025
Is Fuyo General Lease Co. Ltd. (FXL) stock a top pick for value investors - Weekly Earnings Recap & Community Verified Trade Signals - newser.com
Fri, 10 Oct 2025
How geopolitical risks impact Fuyo General Lease Co. Ltd. (FXL) stock - Quarterly Profit Report & Risk Managed Investment Strategies - newser.com
Thu, 11 Sep 2025
ETF Talk: Spread Your Risk with This ETF - Stock Investor
Mon, 01 Sep 2025
Should You Invest in the First Trust Technology AlphaDEX ETF (FXL)? - Yahoo Finance
Sat, 12 Jul 2025
Through its genoprotective, mitochondrial bioenergetic modulation, and antioxidant effects, Fucoxanthin and its metabolite minimize Ochratoxin A-induced nephrotoxicity in HK-2 human kidney cells - BMC Nephrology
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
